Carcinoma, Non-Small-Cell Lung: all 6,641 studies
Page 7 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingNCT07020221Phase 1/2
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsRecruitingNCT07020117Phase 1
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%RecruitingNCT07020065Phase 2
- GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerRecruitingNCT07017829Phase 2
- D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLCRecruitingNCT07016126Phase 3
- PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 TherapyNot yet recruitingNCT07014215Phase 2
- Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-ImmunotherapyRecruitingNCT07014202Phase 2
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT07012031Phase 1/2
- Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung CancerRecruitingNCT07008742
- Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesRecruitingNCT07008287
- Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational StudyRecruitingNCT07004868
- Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLCRecruitingNCT07003490Not applicable
- Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI ProgressionNot yet recruitingNCT07001995Phase 2
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerRecruitingNCT07001618Phase 2
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasRecruitingNCT06999187Phase 1
- Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLCNot yet recruitingNCT06998719Phase 2
- Liquid BiOpsy, Lung and Colon Cancer in AndaluciAEnrolling by invitationNCT06997458
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
- Prospective Data Collection Initiative on Thoracic MalignanciesRecruitingNCT06996249
- Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06992739Phase 2
- Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation TherapyRecruitingNCT06987890Not applicable
- Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer PatientsRecruitingNCT06987734Phase 2
- Radiation-induced Toxicity of the HeartNot yet recruitingNCT06986291Not applicable
- Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST TrialRecruitingNCT06983899Not applicable
- A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06983743Phase 1
- A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Not yet recruitingNCT06982924Phase 2
- A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLCNot yet recruitingNCT06977828Phase 2
- PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLCRecruitingNCT06977074Phase 2
- Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid TumorsRecruitingNCT06975410Phase 1/2
- Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DMRecruitingNCT06974604Phase 2
- Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant StrategyNot yet recruitingNCT06974097
- Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung CancerRecruitingNCT06972576Phase 1
- High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal MetastasisNot yet recruitingNCT06971406Phase 2
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNot yet recruitingNCT06970782Phase 3
- A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
- Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC PatientsRecruitingNCT06967532
- NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLCNot yet recruitingNCT06966583Phase 1
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruitingNCT06963502Phase 1
- Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung CancerRecruitingNCT06963307
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Phase 2
- Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung CancerEnrolling by invitationNCT06962449
- The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II StudyNot yet recruitingNCT06962189Phase 2
- Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology AnalysisNot yet recruitingNCT06961188Phase 3
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsRecruitingNCT06956690Phase 1/2
- Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationRecruitingNCT06956001Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06955988Phase 1
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsRecruitingNCT06953089Phase 2
- ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)RecruitingNCT06951646Phase 2
- A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingNCT06951464Phase 2
- Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung CancerNot yet recruitingNCT06951399Phase 2
- A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C MutationRecruitingNCT06946927Phase 1
- Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyNot yet recruitingNCT06946836Phase 2
- PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) StudyRecruitingNCT06945484Not applicable
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/2
- Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLCRecruitingNCT06939127Phase 2
- Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLCNot yet recruitingNCT06934590Phase 1
- Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World DataRecruitingNCT06934343
- A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyRecruitingNCT06931717Phase 3
- A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveRecruitingNCT06930794Phase 3
- Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLCRecruitingNCT06929936Phase 2
- Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerRecruitingNCT06928389Phase 3
- Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）RecruitingNCT06927986Phase 3
- A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLCRecruitingNCT06926413Phase 1
- SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLCNot yet recruitingNCT06925048Phase 2
- Cancer of the Lung And SeneScencE - Prospective Cohort 1RecruitingNCT06923618Not applicable
- Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment OptionNot yet recruitingNCT06922266
- Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application DeliveryRecruitingNCT06919874Not applicable
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingNCT06918132Phase 2
- PALACE: Cemiplimab Trial According to ctDNA LevelsRecruitingNCT06917573Phase 2
- BBO-11818 in Adult Subjects With KRAS Mutant CancerRecruitingNCT06917079Phase 1
- A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsRecruitingNCT06914128Phase 1/2
- Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung CancerRecruitingNCT06910761Phase 2
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingNCT06908993Phase 3
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNot yet recruitingNCT06908772Phase 2/3
- Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLCNot yet recruitingNCT06908733Phase 2
- A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCRecruitingNCT06908304Phase 3
- Chemoradiotherapy With Surgery Followed by Consolidation DurvalumabRecruitingNCT06908070Phase 4
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06907615Phase 2
- A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)RecruitingNCT06905197Phase 1
- Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLCNot yet recruitingNCT06904547
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingNCT06903377Phase 1/2
- ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung CancerRecruitingNCT06902272Phase 2
- Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitisRecruitingNCT06899789
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Phase 3
- Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCRecruitingNCT06897046Phase 2
- Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung CancerRecruitingNCT06896890Phase 1/2
- Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLCRecruitingNCT06896422Phase 1
- Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT06895031Phase 2
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingNCT06892548Phase 1/2
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3
- Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLCNot yet recruitingNCT06890182Phase 2
- Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung CancerRecruitingNCT06889467
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Phase 2
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) ProductsEnrolling by invitationNCT06885424
- Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly PatientsEnrolling by invitationNCT06883136
- This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung CancerNot yet recruitingNCT06882174Phase 2
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingNCT06881784Phase 3
- Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCRecruitingNCT06878274Phase 2
- Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung CancerRecruitingNCT06877299Phase 2